Changes in pattern of use, clinical characteristics and persistence rate of hormone replacement therapy among postmenopausal women after the WHI publication

被引:52
作者
Guay, Marie-Pascale
Dragomir, Alice
Pilon, Danielle
Moride, Yola
Perreault, Sylvie
机构
[1] Univ Montreal, Fac Pharm, Montreal, PQ H3C 3J7, Canada
[2] Univ Sherbrooke, Fac Med, Sherbrooke, PQ, Canada
关键词
HRT; clinincal characteristic; persistence rate;
D O I
10.1002/pds.1273
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The WHI was stopped prematurely because of an increased risk of breast cancer, stroke and cardiovascular diseases (CVD) in the hormone replacement therapy (HRT) arm of the trial. Changes in the use of HRT are expected. Objective To assess the impact of the Women's Health Initiative (WHI) publication on the rate of HRT prescription, and the clinical characteristics and persistence rate of new users and its determinants. Methods From the RAMQ databases, the total numbers of HRT prescriptions, and of new HRT's users were calculated between 2 January 1998 and 31 May 2003. To assess the clinical characteristics of women, two retrospective cohorts of new HRT's users were constructed before (pre-WHI) and after (post-WHI) the WHI study publication. The persistence rate after I year of follow-up was estimated using a Kaplan-Meier analysis. Cox regression models were used to estimate the rate ratio of HRT cessation. Results The total numbers of HRT users and of new users declined respectively by 28% and 50% in post-WHI. The standard dosage of HRT was significantly less used, while the proportion of women with risk factors of CVD or at very high risk of coronary artery disease (CAD) did not change. The rate of persistence in the pre-WHI cohort was 59% compared to 45% in the post-WHI (p < 0.0001), and women with risk factors of CVD or at very high risk of CAD were less likely to cease their HRT. Conclusion One year after publication, significant changes had already occurred in the trends of use, women's characteristics and estrogen dosage. No change in the proportion of new users with CVD risk factors or at very high risk of CAD was seen. Copyright (c) 2006 John Wiley & Sons, Ltd.
引用
收藏
页码:17 / 27
页数:11
相关论文
共 33 条
[1]   Effects of conjugated, equine estrogen in postmenopausal women with hysterectomy - The women's health initiative randomized controlled trial [J].
Anderson, GL ;
Limacher, M ;
Assaf, AR ;
Bassford, T ;
Beresford, SAA ;
Black, H ;
Bonds, D ;
Brunner, R ;
Brzyski, R ;
Caan, B ;
Chlebowski, R ;
Curb, D ;
Gass, M ;
Hays, J ;
Heiss, G ;
Hendrix, S ;
Howard, BV ;
Hsia, J ;
Hubbell, A ;
Jackson, R ;
Johnson, KC ;
Judd, H ;
Kotchen, JM ;
Kuller, L ;
LaCroix, AZ ;
Lane, D ;
Langer, RD ;
Lasser, N ;
Lewis, CE ;
Manson, J ;
Margolis, K ;
Ockene, J ;
O'Sullivan, MJ ;
Phillips, L ;
Prentice, RL ;
Ritenbaugh, C ;
Robbins, J ;
Rossouw, JE ;
Sarto, G ;
Stefanick, ML ;
Van Horn, L ;
Wactawski-Wende, J ;
Wallace, R ;
Wassertheil-Smoller, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (14) :1701-1712
[2]   Prescriptions for estrogen replacement therapy in Ontario before and after publication of the Women's Health Initiative study [J].
Austin, PC ;
Mamdani, MM ;
Tu, K ;
Jaakkimainen, L .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (24) :3241-3242
[3]  
BELSLEY DA, 1981, REGRESSION DIAGNOSTI
[4]   Postmenopausal hormone replacement therapy for primary prevention of chronic conditions: Recommendations and rationale [J].
Berg, AO ;
Allan, JD ;
Frame, P ;
Homer, CJ ;
Johnson, MS ;
Klein, JD ;
Lieu, TA ;
Orleans, CT ;
Peipert, JF ;
Pender, NJ ;
Siu, AL ;
Teutsch, SM ;
Woolf, SH .
ANNALS OF INTERNAL MEDICINE, 2002, 137 (10) :834-839
[5]  
BLAKE J, 2002, JOGC, V24, P1
[6]   Depression is a risk factor for noncompliance with medical treatment -: Meta-analysis of the effects of anxiety and depression on patient adherence [J].
DiMatteo, MR ;
Lepper, HS ;
Croghan, TW .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (14) :2101-2107
[7]   LONG-TERM ESTROGEN REPLACEMENT THERAPY PREVENTS BONE LOSS AND FRACTURES [J].
ETTINGER, B ;
GENANT, HK ;
CANN, CE .
ANNALS OF INTERNAL MEDICINE, 1985, 102 (03) :319-324
[8]   Determinants of hormone replacement therapy duration among postmenopausal women with intact uteri [J].
Gavin, NI ;
Thorp, JM ;
Ohsfeldt, RL .
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2001, 8 (05) :377-383
[9]   Postmenopausal estrogen and progestin use and the risk of cardiovascular disease [J].
Grodstein, F ;
Stampfer, MJ ;
Manson, JE ;
Colditz, GA ;
Willett, WC ;
Rosner, B ;
Speizer, FE ;
Hennekens, CH .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (07) :453-461
[10]   Insulin resistance implications for type II diabetes mellitus and coronary heart disease [J].
Haffner, SM ;
Miettinen, H .
AMERICAN JOURNAL OF MEDICINE, 1997, 103 (02) :152-162